← All trials
NCT00235495
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2006
- Primary completion
- Feb 1, 2013
- Completion date
- Jun 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 843
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of MiamiLead sponsor
- University of CalgaryOverall official - principal investigator
- Medical University of South CarolinaOverall official - principal investigator
- University of MiamiStudy chair
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- University of CalgaryCollaborator
- Medical University of South CarolinaCollaborator
- Neurological Emergencies Treatment Trials NetworkCollaborator
- University of MiamiReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.